Improve sleep with bright light

Trial ID
NCT06129942
Official Title
Light Therapy in Parkinson's Disease: a Prospective, Observational Study
Goal
Improve sleep with bright light
Phase
NA
Status
RECRUITING
Sponsor
Second Affiliated Hospital of Soochow University
Study Type
INTERVENTIONAL
Enrollment
50 participants
Conditions
Parkinson Disease, Sleep Disorder, Circadian Rhythm Disorders
Interventions
Bright light box, Dim Light box

Plain-Language Summary

The trial is testing whether daily light therapy can improve sleep and circadian rhythm problems in people with moderate Parkinson's, with the goal of improving nighttime sleep, daytime alertness, and overall function. Participants use either a bright light box or a dim light box as a control, with light exposure stimulating the retina to reset the brain's circadian clock and boost wakefulness; it does not directly change how levodopa works, and everyone keeps their Parkinson's medications stable during the study. They are looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stages 2 to 3 who have had stable Parkinson's meds for at least one month and agree not to change them. People with major visual problems, significant cognitive impairment (MMSE under 24), uncontrolled psychiatric symptoms, current use of hypnotics or stimulants, or major circadian disruptions like shift work or recent jet lag are excluded; antidepressants are allowed only if the dose has been stable for more than three months.

Locations

  • Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Frequently Asked Questions

What is this trial testing?
This trial is studying Bright light box. The trial is testing whether daily light therapy can improve sleep and circadian rhythm problems in people with moderate Parkinson's, with the goal of improving nighttime sleep, daytime alertness, and overall function. Participants use either a bright light box or a dim light box as a control, with light exposure stimulating the retina to reset the brain's circadian clock and boost wakefulness; it does not directly change how levodopa works, and everyone keeps their Parkinson's medications stable during the study. They are looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stages 2 to 3 who have had stable Parkinson's meds for at least one month and agree not to change them. People with major visual problems, significant cognitive impairment (MMSE under 24), uncontrolled psychiatric symptoms, current use of hypnotics or stimulants, or major circadian disruptions like shift work or recent jet lag are excluded; antidepressants are allowed only if the dose has been stable for more than three months.
Who can participate?
Participants must be between 50 Years and 80 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 4 years and 8 months.

View on ClinicalTrials.gov